Skip to content 
OUR MAMS PLATFORM TRIALS
SLEIPNIR is a pioneering platform designed to test multiple compounds for target engagement in parallel, advancing only the most promising candidates to HYDRA.
HYDRA is a phase III trial platform that will investigate whether candidate treatments that pass testing at SLEIPNIR can slow or stop the progression of Parkinson’s disease.
WHAT ARE MULTI-ARM MULTI-STAGE (MAMS) PLATFORM TRIALS?
MAMS is a flexible and adaptative design that answers multiple research questions simultaneously, by allowing several treatments to be tested at the same time against a single placebo group. Promising therapies can move forward, while those that show little or no benefit are stopped early. New treatments can also be added along the way. After a short wash-out period—time needed to clear the effects of a previous treatment—participants can switch into other study arms. This approach makes it possible to identify effective therapies more efficiently.
ADVANTAGES OF MAMS STUDIES
FLEXIBILITY
Multiple treatments tested simultaneously, allowing early detection of ineffective arms and their replacement for promising interventions.
ANSWER MULTI QUESTIONS
Answer multi questions under a single trial and regulatory framework, rather than answering them separately in different trials, as in traditional designs.
LESS PATIENTS
Reduces the number of patients treated at ineffective arms while it maximises the number of participants on more efficient treatments.
FASTER AND LESS COSTLY
With no need to set up an entire new clinical trial for each new intervention, MAMS trials are faster and less costly.
